M Volm
- Oncology top 0.5%
- Drug Transport and Resistance Mechanisms 56
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism 17
- Molecular Biology top 2%
- Cancer therapeutics and mechanisms 38
- RNA modifications and cancer 18
- Glutathione Transferases and Polymorphisms 17
- Angiogenesis and VEGF in Cancer 17
-
- Lung Cancer Treatments and Mutations 47
- Pharmacology top 1%
-
- Acute Lymphoblastic Leukemia research 17
M Volm
266 papers receiving 6.2k citations
Peers
Comparison fields: 5 of 130
- Oncology 3.0k
- Cancer Research 1.5k
- Molecular Biology 3.6k
- Pulmonary and Respiratory Medicine 1.2k
- Pharmacology 277
Countries citing papers authored by M Volm
This map shows the geographic impact of M Volm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Volm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Volm more than expected).
Fields of papers citing papers by M Volm
This network shows the impact of papers produced by M Volm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Volm. The network helps show where M Volm may publish in the future.
Co-authorship network
The 25 scholars most cited alongside M Volm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 56 | |
| 2 | 2008 | 149 | |
| 3 | 2008 | 0 | |
| 4 | 2002 | 12 | |
| 5 | 1997 | 184 | |
| 6 | 1997 | 11 | |
| 7 | 1997 | 19 | |
| 8 | 1997 | 24 | |
| 9 | 1996 | 12 | |
| 10 | 1996 | 20 | |
| 11 | Reversal of doxorubicin-resistance in solid tumors by clomipramine. | 1995 | 15 |
| 12 | P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. | 1993 | 15 |
| 13 | 1993 | 27 | |
| 14 | 1992 | 18 | |
| 15 | Polysomal polyadenylated RNA and albumin messenger RNA in Mastomys liver and in a chemically induced hepatocellular carcinoma. | 1982 | 1 |
| 16 | [Short-term incubation in vitro with precursors of nucleic acids on human primary tumors and metastases of carcinoma of the breast (author's transl)]. | 1978 | 4 |
| 17 | 1977 | 2 | |
| 18 | 1975 | 3 | |
| 19 | [Correlation of in vitro testing and therapeutical results in animal transplanted tumors after cytostatic treatment]. | 1975 | 1 |
| 20 | 1974 | 4 |
About M Volm
M Volm is a scholar working on Oncology, Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine and Biotechnology, having authored 278 papers that have together received 6.5k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (56 papers), Lung Cancer Treatments and Mutations (47 papers), Cancer therapeutics and mechanisms (38 papers), RNA modifications and cancer (18 papers), Glutathione Transferases and Polymorphisms (17 papers), Angiogenesis and VEGF in Cancer (17 papers), Cancer, Hypoxia, and Metabolism (17 papers) and Acute Lymphoblastic Leukemia research (17 papers). The work is most often cited by research in Oncology (3.0k citations), Cancer Research (1.5k citations), Molecular Biology (3.6k citations), Pulmonary and Respiratory Medicine (1.2k citations) and Pharmacology (277 citations). M Volm has collaborated with scholars based in Germany, Hungary and United States. Frequent co-authors include Reet Koomägi, J Mattern, Thomas Efferth, Jürgen Mattern, K. Wayss, G. Stammler, Axel Sauerbrey, P. Drings, F Zintl and Werner Rittgen. Their work appears in journals such as International Journal of Oncology, British Journal of Cancer, Die Naturwissenschaften, International Journal of Cancer and Journal of Cancer Research and Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.